ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra ...
Actemra (tocilizumab) is a prescription drug that’s used for arthritis and other conditions. The drug is given as an injection under the skin or an intravenous (IV) infusion. Actemra’s dosage depends ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...
Actemra (tocilizumab) is a prescription drug that’s used to treat arthritis and other conditions. Actemra’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results